Abstract
Clinical trials showed both pembrolizumab alone (KN024), and pembrolizumab/platinum doublet chemotherapy (PDC) (KN189/407) are superior to PDC in 1st-line setting for advanced NSCLC without EGFR/ALK aberration. In PDL1≥50% subset across 3 trials, objective response rate (ORR) with pembrolizumab in KN024 was 45%, compared to 60% with pembrolizumab/PDP in KN189/407 with comparable 12 months overall survival (OS). Recent 5-year survival data from KN024 showed 32% of patients were alive at 5 years, most of whom were “responders”.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
